Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 13/20 | 0.44 |
| ▸ | JAK1 | P23458 | 8/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.42 |
| ▸ | TYK2 | P29597 | 4/20 | 0.41 |
| ▸ | JAK3 | P52333 | 3/20 | 0.41 |
| ▸ | EIF2AK4 | Q9P2K8 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16245609 | 0.92 | JAK2 (0.42) | JAK2JAK1RPS6KA3TYK2JAK3 | |
| SCHEMBL16245580 | 0.90 | RPS6KA3 (0.46) | RPS6KA3JAK3FAAH | |
| SCHEMBL16245553 | 0.88 | RPS6KA3 (0.45) | RPS6KA3JAK3FAAH | |
| SCHEMBL16245542 | 0.87 | RPS6KA3 (0.52) | RPS6KA3JAK3FAAH | |
| SCHEMBL18869218 | 0.86 | JAK1 (0.41) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL16245605 | 0.85 | RPS6KA3 (0.51) | RPS6KA3JAK3FAAH | |
| SCHEMBL16246167 | 0.84 | ITK (0.46) | JAK2JAK1TYK2JAK3HDAC6 | |
| SCHEMBL16245707 | 0.81 | EIF2AK4 (0.47) | JAK2JAK1TYK2JAK3EIF2AK4 | |
| SCHEMBL16264888 | 0.81 | ITK (0.48) | RPS6KA3JAK3 | |
| SCHEMBL16245576 | 0.81 | EGFR (0.46) | JAK2JAK1TYK2JAK3HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9861635-B2 | Macrocycles as kinase inhibitors | MERCK PATENT GMBH (DE) | 2018-01-09 | — | — | US | disclosed |
| US-9861635-B2 | Macrocycles as kinase inhibitors | MERCK PATENT GMBH (DE) | 2018-01-09 | — | — | US | disclosed |
| EP-2994471-B1 | MACROCYCLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2017-05-17 | — | — | EP | disclosed |
| EP-2994471-B1 | MACROCYCLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2017-05-17 | — | — | EP | disclosed |
| US-20160166574-A1 | MACROCYCLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | US | disclosed |
| US-20160166574-A1 | MACROCYCLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | US | disclosed |
| US-20160166574-A1 | MACROCYCLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | US | disclosed |
| EP-2994471-A1 | MACROCYCLES AS KINASE INHIBITORS | Merck Patent GmbH (DE) | 2016-03-16 | — | — | EP | disclosed |
| WO-2014180524-A1 | MACROCYCLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | WO | disclosed |
| WO-2014180524-A1 | MACROCYCLES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166574-A1 | MACROCYCLES AS KINASE INHIBITORS | EIF2AK4, CDK2, CDK1 | JAK2 267/4885JAK1 426/4885RPS6KA3 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.